{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:17Z","timestamp":1787671877361,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05558-5","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:45:11Z","timestamp":1780980311000},"page":"18481-18488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for immune checkpoint inhibitor-related interstitial lung disease: a retrospective cohort study"],"prefix":"10.1007","volume":"399","author":[{"given":"Takahiro","family":"Amemiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"10","key":"5558_CR1","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","volume":"145","author":"AR Abolhassani","year":"2019","unstructured":"Abolhassani AR, Schuler G, Kirchberger Mea, Kirchberger MC et al (2019) C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol 145(10):2625\u20132631. https:\/\/doi.org\/10.1007\/s00432-019-03002-1","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"5558_CR2","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1634\/theoncologist.2019-0550","volume":"25","author":"M Aso","year":"2020","unstructured":"Aso M, Toi Y, Sugisaka Jea et al (2020) Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer. Oncologist 25(3):e536\u2013e544. https:\/\/doi.org\/10.1634\/theoncologist.2019-0550","journal-title":"Oncologist"},{"key":"5558_CR3","doi-asserted-by":"publisher","unstructured":"Chen Y, Xu L, Zou S, Chen J, Xu X (2025) Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis. Hum Vaccin Immunother 21(1):2564554, 2564554. https:\/\/doi.org\/10.1080\/21645515.2025.2564554","DOI":"10.1080\/21645515.2025.2564554"},{"issue":"1","key":"5558_CR4","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","volume":"20","author":"J Choi","year":"2020","unstructured":"Choi J, Lee SY (2020) Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw 20(1):e9. https:\/\/doi.org\/10.4110\/in.2020.20.e9","journal-title":"Immune Netw"},{"issue":"12","key":"5558_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair Vea et al (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1","journal-title":"Exp Mol Med"},{"issue":"9","key":"5558_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005323","volume":"10","author":"A Franken","year":"2022","unstructured":"Franken A, Van Mol P, Vanmassenhove Sea et al (2022) Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. J Immunother Cancer 10(9):e005323. https:\/\/doi.org\/10.1136\/jitc-2022-005323","journal-title":"J Immunother Cancer"},{"key":"5558_CR7","doi-asserted-by":"publisher","unstructured":"Guo X, Chen S, Wang Xea et al (2023) Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: diagnosis, mechanism, and treatment strategies. Front Immunol 14:1138483, 1138483. https:\/\/doi.org\/10.3389\/fimmu.2023.1138483","DOI":"10.3389\/fimmu.2023.1138483"},{"issue":"1","key":"5558_CR8","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/oncolo\/oyad187","volume":"29","author":"K Horiuchi","year":"2024","unstructured":"Horiuchi K, Ikemura S, Sato Tea et al (2024) Pre-existing interstitial lung abnormalities and immune checkpoint inhibitor-related pneumonitis in solid tumors: a retrospective analysis. Oncologist 29(1):e108\u2013e117. https:\/\/doi.org\/10.1093\/oncolo\/oyad187","journal-title":"Oncologist"},{"issue":"4","key":"5558_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi Jea et al (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19(4):254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nat Rev Clin Oncol"},{"key":"5558_CR10","doi-asserted-by":"publisher","unstructured":"Lavalle S, Masiello E, Valerio Mea, Valerio M et al (2024) Immune checkpoint inhibitor therapy-related pneumonitis: how, when and why to diagnose and manage (review). Exp Ther Med 28(4):381, 381. https:\/\/doi.org\/10.3892\/etm.2024.12670","DOI":"10.3892\/etm.2024.12670"},{"key":"5558_CR11","doi-asserted-by":"publisher","unstructured":"Lin MX, Zang D, Liu Cea, Liu C-G et al (2024) Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. Front Immunol 15:1266850, 1266850. https:\/\/doi.org\/10.3389\/fimmu.2024.1266850","DOI":"10.3389\/fimmu.2024.1266850"},{"key":"5558_CR12","doi-asserted-by":"publisher","unstructured":"Ma K, Lu Y, Jiang Sea et al (2018) The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol 9:1430, 1430. https:\/\/doi.org\/10.3389\/fphar.2018.01430","DOI":"10.3389\/fphar.2018.01430"},{"key":"5558_CR13","doi-asserted-by":"publisher","unstructured":"Meng L, Wu H, Wu Jea et al (2024) Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAs involved in cancer hallmarks. Cell Death Dis 15(1):3, 3. https:\/\/doi.org\/10.1038\/s41419-023-06389-5","DOI":"10.1038\/s41419-023-06389-5"},{"key":"5558_CR14","doi-asserted-by":"publisher","unstructured":"Morgado M, Pl\u00e1cido A, Morgado Sea et al (2020) Management of the adverse effects of immune checkpoint inhibitors. Vaccines 8(4):575, 575. https:\/\/doi.org\/10.3390\/vaccines8040575","DOI":"10.3390\/vaccines8040575"},{"key":"5558_CR15","doi-asserted-by":"publisher","unstructured":"Mu-Mosley H, von Itzstein MS, Fattah Fea et al (2024) Distinct autoantibody profiles across checkpoint inhibitor types and toxicities. Oncoimmunology 13(1):2351255, 2351255. https:\/\/doi.org\/10.1080\/2162402X.2024.2351255","DOI":"10.1080\/2162402X.2024.2351255"},{"issue":"7","key":"5558_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo Kea et al (2017) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35(7):709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"5558_CR17","doi-asserted-by":"publisher","first-page":"13773","DOI":"10.1038\/s41598-020-70743-2","volume":"10","author":"N Okada","year":"2020","unstructured":"Okada N, Matsuoka R, Sakurada T et al (2020) Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci Rep 10(1):13773. https:\/\/doi.org\/10.1038\/s41598-020-70743-2","journal-title":"Sci Rep"},{"issue":"6382","key":"5558_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"6","key":"5558_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","volume":"64","author":"D Schmidt-Arras","year":"2016","unstructured":"Schmidt-Arras D, Rose-John S (2016) IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol 64(6):1403\u20131415. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.004","journal-title":"J Hepatol"},{"issue":"7","key":"5558_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1164\/rccm.201803-0525RR","volume":"198","author":"R Sternschein","year":"2018","unstructured":"Sternschein R, Moll M, Ng Jea et al (2018) Immune checkpoint inhibitor-related pneumonitis. Incidence, risk factors, and clinical and radiographic features. Am J Respir Crit Care Med 198(7):951\u2013953. https:\/\/doi.org\/10.1164\/rccm.201803-0525RR","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5558_CR21","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/1759-7714.13364","volume":"11","author":"T Sugano","year":"2020","unstructured":"Sugano T, Seike M, Saito Yea et al (2020) Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 11(4):1052\u20131060. https:\/\/doi.org\/10.1111\/1759-7714.13364","journal-title":"Thorac Cancer"},{"issue":"6","key":"5558_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin Cea et al (2018) <article-title update=\"added\">Immune checkpoint immunotherapy for non-small cell lung cancer. Chest 154(6):1416\u20131423. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048","journal-title":"Chest"},{"issue":"44","key":"5558_CR23","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir SA, Gao J, Miura Yea et al (2019) Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246\u201322251. https:\/\/doi.org\/10.1073\/pnas.1908079116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5558_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12885-026-15729-5","volume":"26","author":"D Tao","year":"2026","unstructured":"Tao D, Lei H, Sun Lea et al (2026) Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients. BMC Cancer 26(1):373. https:\/\/doi.org\/10.1186\/s12885-026-15729-5","journal-title":"BMC Cancer"},{"key":"5558_CR25","doi-asserted-by":"publisher","unstructured":"Tay SH, Toh MMX, Thian Yea, Thian YL et al (2022) Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13:807050, 807050. https:\/\/doi.org\/10.3389\/fimmu.2022.807050","DOI":"10.3389\/fimmu.2022.807050"},{"issue":"12","key":"5558_CR26","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"1","key":"5558_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1759-7714.13240","volume":"11","author":"H Wang","year":"2020","unstructured":"Wang H, Guo X, Zhou J, Wang Mea et al (2020) Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer 11(1):191\u2013197. https:\/\/doi.org\/10.1111\/1759-7714.13240","journal-title":"Thorac Cancer"},{"key":"5558_CR28","doi-asserted-by":"publisher","unstructured":"Wei J, Li W, Zhang Pea et al (2024) Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer 23(1):279, 279. https:\/\/doi.org\/10.1186\/s12943-024-02179-5","DOI":"10.1186\/s12943-024-02179-5"},{"key":"5558_CR29","doi-asserted-by":"publisher","unstructured":"Yin Q, Wu L, Han Lea et al (2023) Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol 14:1167975, 1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"5558_CR30","doi-asserted-by":"publisher","unstructured":"Zhang Z, Zhang L, Wang K, Zhang Xea et al (2024) Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis. NPJ Precis Oncol 8(1):226, 226. https:\/\/doi.org\/10.1038\/s41698-024-00715-6","DOI":"10.1038\/s41698-024-00715-6"},{"key":"5558_CR31","doi-asserted-by":"publisher","unstructured":"Zhou X, Xu Y, Ying Yea et al (2025) Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol 16:1607170, 1607170. https:\/\/doi.org\/10.3389\/fimmu.2025.1607170","DOI":"10.3389\/fimmu.2025.1607170"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05558-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:03:09Z","timestamp":1787670189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05558-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5558"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05558-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects and was approved by the Ethics Committee of the Faculty of Medicine, University of Tokyo (approval number: 2529).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived by the Ethics Committee because this retrospective observational study used pre-existing clinical data, involved no intervention or invasion, and obtaining individual informed consent from all eligible patients was considered impracticable. In accordance with the Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects in Japan and the requirements of the Ethics Committee, information about the study was disclosed to the participants, and an opt-out opportunity was provided.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (AI) tools, including large language models and machine learning software, were used for data analysis and literature searches for this manuscript.","order":6,"name":"Ethics","label":"Artificial Intelligence (AI) Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}